Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Total Debt (2019 - 2025)

Puma Biotechnology (PBYI) has disclosed Total Debt for 7 consecutive years, with $22.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Debt fell 66.41% year-over-year to $22.5 million, compared with a TTM value of $22.5 million through Dec 2025, down 66.41%, and an annual FY2025 reading of $22.5 million, down 66.41% over the prior year.
  • Total Debt was $22.5 million for Q4 2025 at Puma Biotechnology, down from $33.7 million in the prior quarter.
  • Across five years, Total Debt topped out at $100.1 million in Q2 2021 and bottomed at $22.5 million in Q4 2025.
  • Average Total Debt over 5 years is $83.6 million, with a median of $97.5 million recorded in 2022.
  • The sharpest move saw Total Debt surged 600.93% in 2021, then tumbled 66.41% in 2025.
  • Year by year, Total Debt stood at $97.1 million in 2021, then increased by 1.25% to $98.3 million in 2022, then increased by 1.37% to $99.7 million in 2023, then crashed by 32.72% to $67.0 million in 2024, then crashed by 66.41% to $22.5 million in 2025.
  • Business Quant data shows Total Debt for PBYI at $22.5 million in Q4 2025, $33.7 million in Q3 2025, and $44.9 million in Q2 2025.